Latest & greatest articles for hiv

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hiv or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hiv and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hiv

1. Improving the diagnosis and treatment of smear-negative pulmonary and extrapulmonary tuberculosis among adults and adolescents. Recommendations for HIV-prevalent and resource-constrained settings.

Improving the diagnosis and treatment of smear-negative pulmonary and extrapulmonary tuberculosis among adults and adolescents. Recommendations for HIV-prevalent and resource-constrained settings. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ

2010 World Health Organization

2. HIVMA of IDSA Clinical Practice Guideline for the Management of Chronic Pain in Patients Living With HIV

HIVMA of IDSA Clinical Practice Guideline for the Management of Chronic Pain in Patients Living With HIV Practice Guidelines Search Search Practice Guidelines Practice guidelines are systematically developed statements to assist practitioners and patients in making decisions about appropriate health care for specific clinical circumstances. Attributes of good guidelines include validity, reliability, reproducibility, clinical applicability, clinical flexibility, clarity, multidisciplinary

2017 Infectious Diseases Society of America

3. Effectiveness of peer education interventions for HIV prevention, adolescent pregnancy prevention and sexual health promotion for young people: a systematic review of European studies

Effectiveness of peer education interventions for HIV prevention, adolescent pregnancy prevention and sexual health promotion for young people: a systematic review of European studies Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

4. Isoniazid for preventing tuberculosis in HIV-infected children. (PubMed)

Isoniazid for preventing tuberculosis in HIV-infected children. Tuberculosis (TB) is an important cause of illness and death in HIV-positive children living in areas of high TB prevalence. We know that isoniazid prophylaxis prevents TB in HIV-negative children following TB exposure, but there is uncertainty related to its role in TB preventive treatment in HIV-positive children.To summarise the effects of TB preventive treatment versus placebo in HIV-positive children with no known TB contact (...) on active TB, death, and reported adverse events.We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE/PubMed, Embase and two trial registers up to February 2017.We included trials of HIV-positive children with and without known TB exposure, randomized to receive TB preventive treatment or placebo.Two review authors independently used the study selection criteria, assessed risk of bias, and extracted data. We assessed effects using risk, incidence rate and hazard ratios

Full Text available with Trip Pro

2017 Cochrane

5. Challenges faced by HIV-positive youth transitioning to adult care and evidence-based practices to address them

Challenges faced by HIV-positive youth transitioning to adult care and evidence-based practices to address them Challenges faced by HIV-positive youth transitioning to adult care and evidence-based practices to address them | The Ontario HIV Treatment Network The Ontario HIV Treatment Network Challenges faced by HIV-positive youth transitioning to adult care and evidence-based practices to address them Challenges faced by HIV-positive youth transitioning to adult care and evidence-based (...) practices to address them , , , , Questions What challenges arise when youth living with HIV transition to adult care? What evidence-based practices and resources facilitate successful transition to adult HIV care? Key take-home messages The barriers to successful transition to adult HIV care include lack of preparation, psychosocial stressors, loss of relationships, stigma, and barriers within the adult health care system (communication, distance to travel, differences from the pediatric environment

2018 Ontario HIV Treatment Network

7. Nutrition and HIV

Nutrition and HIV Nutrition and HIV | The Ontario HIV Treatment Network The Ontario HIV Treatment Network Nutrition and HIV Nutrition and HIV , , Questions Do people living with symptomatic HIV infection or AIDS require a therapeutic diet? Key take-home messages Nutrition is an important component of care for people living with HIV (1–5). Nutritional needs for people living with HIV can vary; therefore, dietary recommendations should be individualized to meet specific needs (1–3, 6). In general (...) , asymptomatic people living with HIV appear to have greater energy requirements compared to the general population (2, 3, 7–10). After symptomatic periods, it is critical that people living with HIV recover lost weight (6); it is suggested that energy requirements during recovery may be increased by 20-30% (11). Treatment for dyslipidemia, a metabolic complication independently associated with HIV and antiretroviral therapy (12–14), includes dietary management (6, 15–21). Some systematic reviews (22–25

2018 Ontario HIV Treatment Network

8. What is the effectiveness of motivational interviewing in changing risk behaviours (e.g. sex, drug use, medication adherence) for people living with HIV?

What is the effectiveness of motivational interviewing in changing risk behaviours (e.g. sex, drug use, medication adherence) for people living with HIV? Motivational interviewing | The Ontario HIV Treatment Network The Ontario HIV Treatment Network Motivational interviewing Motivational interviewing , , Photo: Question What is the effectiveness of motivational interviewing in changing risk behaviours (e.g. sex, drug use, medication adherence) for people living with HIV? Key Take-Home Messages (...) Interventions that make use of motivational interviewing can be effective in changing risk behaviours for people living with HIV (1-18); the longer the motivational interviewing intervention, the more it may help intervention participants to maintain healthier practices over time (19). For people living with HIV, motivational interviewing can have a positive effect on medication adherence (1;6-9;15;17;18), sexual risk behaviours (3-5;10;11), drug use (2;12;14), and numerous outcomes at the same time (13;16

2014 Ontario HIV Treatment Network

10. The role of peers in linkage, engagement, and retention in HIV care

The role of peers in linkage, engagement, and retention in HIV care The role of peers in linkage, engagement, and retention in HIV care | The Ontario HIV Treatment Network The Ontario HIV Treatment Network The role of peers in linkage, engagement, and retention in HIV care The role of peers in linkage, engagement, and retention in HIV care , , Question What is the role of peers in linkage, engagement, and retention in HIV care? Key take-home messages In the HIV community, a peer is someone (...) living with HIV who contributes to positive health outcomes of other community members, but is not usually a health care professional with clinical training (1-3). Peers have made important contributions in HIV care, playing many roles and providing services such as education and social support (2, 4). Randomized controlled trials of peer programs to improve linkage, engagement and retention in HIV care have not shown significant differences compared to non-peer programs (5-7). More research

2017 Ontario HIV Treatment Network

11. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents

Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents ARV Guidelines | HIV Treatment Guidelines - ASHM Welcome to the Australian Commentary on the US Department of Health and Human Services (DHHS) Guidelines for the use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents The Australian Commentary to the has been prepared by the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) Sub-Committee for Guidance on HIV (...) Management in Australia. For further information about its development please see the and please read the . In addition to the Australian Commentary on the US DHHS Guidelines the ASHM Sub-Committee for Guidance on HIV Management in Australia has been tasked with the development of: The ASHM Sub-Committee for Guidance on HIV Management in Australia has developed specific clinical guidance on the topic of when to start antiretroviral therapy in people with HIV. Key considerations concerning the issue

2011 Clinical Practice Guidelines Portal

12. Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/TBL)

Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/TBL) Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/TBL) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/TBL) (HIV/TB) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01875952 Recruitment Status : Unknown Verified June

2012 Clinical Trials

13. HIV testing: increasing uptake among people who may have undiagnosed HIV (Joint NICE and Public Health England guideline)

HIV testing: increasing uptake among people who may have undiagnosed HIV (Joint NICE and Public Health England guideline) HIV testing: increasing uptak HIV testing: increasing uptake among e among people who ma people who may ha y hav ve undiagnosed HIV e undiagnosed HIV NICE guideline Published: 1 December 2016 nice.org.uk/guidance/ng60 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our (...) of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. HIV testing: increasing uptake among people who may have undiagnosed HIV (NG60) © NICE 2019. All rights reserved

2016 National Institute for Health and Clinical Excellence - Clinical Guidelines

14. Canadian HIV Pregnancy Planning Guidelines

Canadian HIV Pregnancy Planning Guidelines No. 354-Canadian HIV Pregnancy Planning Guidelines - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 40, Issue 1, Pages 94–114 No. 354-Canadian HIV Pregnancy Planning Guidelines x Mona Loutfy , MD, MPH (Principal Author) Toronto, ON x V. Logan Kennedy , RN (Principal Author) Toronto, ON x Vanessa Poliquin , MD (Principal Author) Winnipeg, MB x Frederick Dzineku , MD (Principal (...) and Gynaecology, St. Michael's Hospital, Toronto, ON. , MD (Principal Author)* , x Mark H. Yudin Correspondence Corresponding Author: Dr. Mark Yudin, Department of Obstetrics and Gynaecology, St. Michael's Hospital, Toronto, ON. Toronto, ON No. 354, January 2018 (Replaces No. 278, June 2012) DOI: To view the full text, please login as a subscribed user or . Click to view the full text on ScienceDirect. Abstract Objective The objective of the Canadian HIV Pregnancy Planning Guidelines is to provide clinical

2018 Society of Obstetricians and Gynaecologists of Canada

15. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza) - Human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza) - Human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza ® ). Reference number 2418. Page 1 of 3 Enc 9 Appx 2 AWMSG Secretariat Assessment Report – Limited submission Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza ®? ) 800 mg/150 mg/200 mg/10 mg film-coated tablet Company: Janssen-Cilag Ltd Licensed indication under (...) consideration: Treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents (aged 12 years and older with body weight at least 40 kg). ? This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Marketing authorisation date: 26 September 2017 Comparator(s) ? Darunavir/cobicistat (Rezolsta ® ) in combination with emtricitabine

2018 All Wales Medicines Strategy Group

17. HIV treatment: transition to new antiretrovirals in HIV programmes: policy brief

HIV treatment: transition to new antiretrovirals in HIV programmes: policy brief HIV treatment: transition to new antiretrovirals in HIV programmes: policy brief JavaScript is disabled for your browser. Some features of this site may not work without it. Toggle navigation Toggle navigation Search Browse Statistics Related Links HIV treatment: transition to new antiretrovirals in HIV programmes: policy brief View/ Open Rights View Statistics Altmetrics Share Citation World Health Organization (...) . (‎2017)‎. HIV treatment: transition to new antiretrovirals in HIV programmes: policy brief. World Health Organization. . License: CC BY-NC-SA 3.0 IGO Description 8 p. Gov't Doc # WHO/HIV/2017.20 Collections Language English Metadata Related items Showing items related by title and MeSH subject.  World Health Organization (‎ 2005 )‎  World Health Organization (‎ 2010 )‎  World Health Organization ; Keebler, Daniel ; Revill, Paul ; Braithwaite, Scott ; Phillips, Andrew ; Blaser, Nello ; Borquez

2017 WHO

18. WHO Working Group on HIV incidence assays: estimating HIV incidence using HIV case surveillance: meeting report, Glion, Switzerland, 10–11 December 2015

WHO Working Group on HIV incidence assays: estimating HIV incidence using HIV case surveillance: meeting report, Glion, Switzerland, 10–11 December 2015 WHO Working Group on HIV incidence assays: estimating HIV incidence using HIV case surveillance: meeting report, Glion, Switzerland, 10–11 December 2015 JavaScript is disabled for your browser. Some features of this site may not work without it. Toggle navigation Toggle navigation Search Browse Statistics Related Links WHO Working Group on HIV (...) incidence assays: estimating HIV incidence using HIV case surveillance: meeting report, Glion, Switzerland, 10–11 December 2015 View/ Open Rights View Statistics Altmetrics Share Citation World Health Organization & UNAIDS . (‎2017)‎. WHO Working Group on HIV incidence assays: estimating HIV incidence using HIV case surveillance: meeting report, Glion, Switzerland, 10–11 December 2015. World Health Organization. . License: CC BY-NC-SA 3.0 IGO Description 28 p. Gov't Doc # WHO/HIV/2017.03 Collections

2017 WHO

20. Patients With HIV Do Not Experience Higher Dental Implant Failure Rates Than Patients Without HIV

Patients With HIV Do Not Experience Higher Dental Implant Failure Rates Than Patients Without HIV UTCAT2845, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Patients With HIV Do Not Experience Higher Dental Implant Failure Rates Than Patients Without HIV Clinical Question Are patients with HIV more likely to have dental implant failure than patients without HIV? Clinical Bottom Line Dental implant failure rates (...) in patients with HIV is similar to that seen in patients without HIV. Factors that increase the probability of success in these patients are prophylactic antibiotics, highly active antiretroviral therapy (HAART), and controlled CD4+ T lymphocyte counts. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Ata-Ali/2015 9 studies/173 implants Systematic review of non-randomized trials Key results The authors

2015 UTHSCSA Dental School CAT Library